focus -WSS

focus

author：knowledge 2025-10-01 18:32:16 - browse：63817

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： GOP inquiry over gain

WSS

How clinical AI models' predictive power can degrade over time

Nick Jonas talks about managing diabetes along with his career

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

UnitedHealth wins $3.3 billion takeover of Amedisys

Better Therapeutics data on benefit with GLP

Synthetic human embryos? Researchers say term is overblown

focus

focus

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

A fraught question for the kids of Alzheimer’s: Is it coming for us?

The high cost of giving birth even with insurance

What's changing in Medicare's open enrollment this year?

Affirmative action in medical school literally saved lives

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

United colonoscopy coverage change 'may cost lives,' doctors say

Medical experts exlpore how to eliminate bias in clinical algorithms

In age of alternative facts, a scholarly course on calling out crap

Female surgeons have lower rates of long

hotspot

Wellcome Trust names Røttingen as its new CEO

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Here's how to stay safe from wildfire smoke amid reduced air quality

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Medicare to cover more brain scans related to Alzheimer’s drugs

Life sciences deals on track to hit lowest point since 2017

focus

focus

knowledge

entertainment